Literature DB >> 24210875

Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.

Xianghui Zeng1, Ralf Morgenstern, Andreas M Nyström.   

Abstract

Resistance to single or multiple chemotherapeutic drugs is a major complication in clinical oncology and is one of the most common treatment limitations in patients with reoccurring cancers. Nanoparticle (NP)-based drug delivery systems (DDS's) have been shown to overcome drug resistance in cancer cells mainly by avoiding the activation of efflux pumps in these cells. We demonstrate in this work that polyester-based hyperbranched dendritic-linear (HBDL)-based NPs carrying doxorubicin (Dox) can effectively overcome microsomal glutathione transferase 1 (MGST1)-mediated drug resistance in breast cancer cells. Our DDS was much more effective at considerably lower intracellular Dox concentrations (IC50 6.3 μm vs. 36.3 μm) and achieved significantly greater reductions in viability and induced higher degrees of apoptosis (31% vs. 14%) compared to the free drug in the resistant cells. Dox-loaded HBDL NPs were found to translocate across the membranes of resistant cells via active endocytic pathways and to be transported to lysosomes, mitochondria, and the endoplasmic reticulum. A significantly lower amount of Dox accumulated in these cytoplasmic compartments in resistant cells treated with free Dox. Moreover, we found that Dox-HBDL significantly decreased the expression of MGST1 and enhanced mitochondria-mediated apoptotic cell death compared to free Dox. Dox-HBDL also markedly activated the JNK pathway that contributes to the apoptosis of drug-resistant cells. These results suggest that HBDL NPs can modulate subcellular drug distribution by specific endocytic and trafficking pathways and that this results in drug delivery that alters enzyme levels and cellular signaling pathways and, most importantly, increases the induction of apoptosis. Our findings suggest that by exploiting the cell transport machinery we can optimize the polymeric vehicles for controlled drug release to overcome drug resistance combat drug resistance with much higher efficacy.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Dox; Dox-HBDL; Doxorubicin; Drug delivery; Drug resistance; Endocytosis; Glutathione transferase; JNK; MGST1; Polymeric nanoparticle; c-Jun N-terminal kinase; doxorubicin; hyperbranched dendritic-linear micelles encapsulating doxorubicin; microsomal glutathione transferase 1

Mesh:

Substances:

Year:  2013        PMID: 24210875     DOI: 10.1016/j.biomaterials.2013.10.042

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  29 in total

1.  Synthesis of 4-aryl-6-indolylpyridine-3-carbonitriles and evaluation of their antiproliferative activity.

Authors:  Naglaa Salem El-Sayed; Amir Nasrolahi Shirazi; Magda Goda El-Meligy; Ahmed Kamel El-Ziaty; Zenat Adeeb Nagib; Keykavous Parang
Journal:  Tetrahedron Lett       Date:  2014-02-05       Impact factor: 2.415

2.  ABCG2 aptamer selectively delivers doxorubicin to drug-resistant breast cancer cells.

Authors:  Shirin Hashemitabar; Rezvan Yazdian-Robati; Maryam Hashemi; Mohammad Ramezani; Khalil Abnous; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2019-06       Impact factor: 1.826

3.  Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.

Authors:  Xin Wang; Zhaogang Teng; Haiyan Wang; Chunyan Wang; Ying Liu; Yuxia Tang; Jiang Wu; Jin Sun; Hai Wang; Jiandong Wang; Guangming Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

4.  Facile synthesis and surface modification of bioinspired nanoparticles from quercetin for drug delivery.

Authors:  Suhair Sunoqrot; Eveen Al-Shalabi; Phillip B Messersmith
Journal:  Biomater Sci       Date:  2018-09-25       Impact factor: 6.843

5.  Histamine-functionalized copolymer micelles as a drug delivery system in 2D and 3D models of breast cancer.

Authors:  Yuning Zhang; Pontus Lundberg; Maren Diether; Christian Porsch; Caroline Janson; Nathaniel A Lynd; Cosimo Ducani; Michael Malkoch; Eva Malmström; Craig J Hawker; Andreas M Nyström
Journal:  J Mater Chem B       Date:  2015-03-28       Impact factor: 6.331

6.  Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells.

Authors:  Marike W van Gisbergen; Marcus Cebula; Jie Zhang; Astrid Ottosson-Wadlund; Ludwig Dubois; Philippe Lambin; Kenneth D Tew; Danyelle M Townsend; Guido R M M Haenen; Marie-José Drittij-Reijnders; Hisao Saneyoshi; Mika Araki; Yuko Shishido; Yoshihiro Ito; Elias S J Arnér; Hiroshi Abe; Ralf Morgenstern; Katarina Johansson
Journal:  Mol Pharm       Date:  2016-04-28       Impact factor: 4.939

7.  Remote Loading of Small-Molecule Therapeutics into Cholesterol-Enriched Cell-Membrane-Derived Vesicles.

Authors:  Xinxin Zhang; Pavimol Angsantikul; Man Ying; Jia Zhuang; Qiangzhe Zhang; Xiaoli Wei; Yao Jiang; Yue Zhang; Diana Dehaini; Mengchun Chen; Yijie Chen; Weiwei Gao; Ronnie H Fang; Liangfang Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-05       Impact factor: 15.336

Review 8.  Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.

Authors:  P S Thakur; A M Khan; S Talegaonkar; F J Ahmad; Z Iqbal
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-26       Impact factor: 4.553

9.  Doxorubicin loaded nanodiamond-silk spheres for fluorescence tracking and controlled drug release.

Authors:  Asma Khalid; Alexander N Mitropoulos; Benedetto Marelli; Snjezana Tomljenovic-Hanic; Fiorenzo G Omenetto
Journal:  Biomed Opt Express       Date:  2015-12-15       Impact factor: 3.732

10.  Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.

Authors:  Hai Wang; Pranay Agarwal; Shuting Zhao; Ronald X Xu; Jianhua Yu; Xiongbin Lu; Xiaoming He
Journal:  Biomaterials       Date:  2015-08-29       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.